Page last updated: 2024-10-26

etodolac and Cancer of Head

etodolac has been researched along with Cancer of Head in 1 studies

Etodolac: A non-steroidal anti-inflammatory agent and cyclooxygenase-2 (COX-2) inhibitor with potent analgesic and anti-arthritic properties. It has been shown to be effective in the treatment of OSTEOARTHRITIS; RHEUMATOID ARTHRITIS; ANKYLOSING SPONDYLITIS; and in the alleviation of postoperative pain (PAIN, POSTOPERATIVE).
etodolac : A monocarboxylic acid that is acetic acid in which one of the methyl hydrogens is substituted by a 1,8-diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indol-1-yl moiety. A preferential inhibitor of cyclo-oxygenase 2 and non-steroidal anti-inflammatory, it is used for the treatment of rheumatoid arthritis and osteoarthritis, and for the alleviation of postoperative pain. Administered as the racemate, only the (S)-enantiomer is active.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Murata, S1
Adachi, M1
Kioi, M1
Torigoe, S1
Ijichi, K1
Hasegawa, Y1
Ogawa, T1
Bhayani, MK1
Lai, SY1
Mitsudo, K1
Tohnai, I1

Other Studies

1 other study available for etodolac and Cancer of Head

ArticleYear
Etodolac improves 5-FU sensitivity of head and neck cancer cells through inhibition of thymidylate synthase.
    Anticancer research, 2011, Volume: 31, Issue:9

    Topics: Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Cyclooxygenase 2; Down-Regulation; Enzym

2011